Open notice
Advance the development of SCY-247, a novel antifungal currently in Phase 1 clinical trials, for the treatment of invasive candidiasis and prophylaxis of invasive fungal disease as oral and IC formula
Award Notice. Posted by BARDA - ASPR / DAAPPO / BARDA DCMA. No response date stated.
Read from the SAM.gov opportunities API and refreshed daily. The original notice is linked at the foot of this page.
The notice as published
| Field | As posted |
|---|---|
| Notice type | Award Notice |
| Solicitation number | BAA-23-100-SOL-00004 |
| Posted | Sep 25, 2026 |
| Responses close | not stated |
| Buying office | BARDA - ASPR / DAAPPO / BARDA DCMA |
| Department | HEALTH AND HUMAN SERVICES, DEPARTMENT OF |
| Place of performance | Jersey City NJ |
| Awarded to | Scynexis, Inc. for $213.94M |
Shown exactly as the source published it. Where a field is blank on the notice it says so rather than being filled in.
Who is named on it
| Name | Role | |
|---|---|---|
| Audrey Glover | not stated | audrey.glover@hhs.gov |
| Veronica Stroud | not stated | veronica.stroud@hhs.gov |
Published on the notice by the contracting office. Before the solicitation closes, contact is limited to the formal question process the notice describes.
See who was last awarded in your NAICS
Every code, every buying office, every vendor and every recompete, organized from the federal record and read nightly. Open it with a plan.